Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00556660 is registered in ClinicalTrials.gov with Institute for Neurodegenerative Disorders as lead sponsor.

NCT NCT00556660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00556660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Lead sponsor
Institute for Neurodegenerative Disorders
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2007
Completion date
July 31, 2008
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease